Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
DUBLIN , Feb. 26, 2016 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2015 on Thursday, March 3, 2016. The Company has scheduled a conference call for that same day, Thursday, March 3, 2016 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |
| International: | 1-412-317-6581 | |
| Conference ID #: | 10081700 | |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/13669
A replay of the call can be accessed until March 10, 2016 by dialing:
| USA: | 1-877-344-7529 | |
| International: | 1-412-317-0088 | |
| Conference ID #: | 10081700 | |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/13669
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
